Evaluation of ear, nose and throat involvement in pemphigus vulgaris in comparison with pemphigus severity scoring systems: a cross-sectional study by Aslı Bilgic Temel et al.
283ACTA DERMATOVENEROLOGICA CROATICA
Acta Dermatovenerol Croat                           2018;26(4):283-288                 OriginAl sCientifiC ArtiCle
Evaluation of Ear, Nose, and Throat Involvement in 
Pemphigus Vulgaris in Comparison with Pemphigus 
Severity Scoring Systems: A Cross-sectional Study
Aslı Bilgic-Temel*1, Ismail Cem Temel*2, Aslı Bostancı-Toptas3,  
Murat Turhan3, Selen Bozkurt4, Soner Uzun5
*First co-authors
1Beysehir State Hospital, Dermatology Clinic, Konya, Turkey; 2Seydisehir State Hospital, 
Ear, Nose, and Throat Clinic, Konya, Turkey; 3Akdeniz University, Faculty of Medicine, 
Ear, Nose, and Throat Department, Antalya, Turkey; 4Akdeniz University, Faculty of 
Medicine, Biostatistics and Medical Informatics Department, Antalya, Turkey; 5Akdeniz 
University, Faculty of Medicine, Department of Dermatology and Venereology,  
Antalya, Turkey
Corresponding author:







received: January 8, 2108
Accepted: november 5, 2018
ABSTRACT Pemphigus vulgaris (PV) frequently affects the mucous 
membranes of the ear, nose, and throat (ent). since ent examination 
is not a routinely performed procedure, the exact involvement of PV 
remains unrecognized. the available severity scoring systems (Pem-
phigus Disease Area index (PDAi) and Autoimmune Bullous skin Dis-
order intensity score (ABsis)) for PV do not include a full ent examina-
tion. this study was designed to evaluate the real extent of PV in ent 
areas and to find out the specific scores which indicate the need for 
ent examination. the patients were evaluated for ent manifestations 
by endoscopic examination whether or not they exhibited symp-
toms. PDAi, ABsis, and ent scores were calculated, and the results 
were compared for correlation and significance. the mucosal involve-
ment was more severe when scored by ent examination than when 
assessed by PDAi or ABsis. the ent score was significantly associated 
with symptoms and endoscopic findings, especially when PDAi ≥15 
and/or ABsis ≥17. ent endoscopic examination could result in more 
accurate grading in PV. in particular, performing such an examination 
should be considered in patients, especially when PDAi ≥15 and/or 
ABsis ≥17, regardless of ent symptoms.
KEY WORDS: pemphigus vulgaris, ear, nose, and throat, mucosa, dis-
ease severity, PDAi (Pemphigus Disease Area index), ABsis (Autoim-
mune Bullous skin Disorder intensity score)
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INTRODUCTION
Pemphigus is a potentially life-threatening, auto-
immune blistering disease of the skin and mucous 
membranes. it is mediated by autoantibodies which 
target the transmembranous adhesion glycoproteins 
desmoglein 1 (Dsg1) and desmoglein 3 (Dsg3). Pem-
phigus vulgaris (PV) is the major subtype of pemphi-
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gus, characterized as having a progressive course 
which may lead to death if not treated. involvement 
of mucosal areas in PV significantly increases patient 
morbidity and mortality. since endoscopic ear, nose, 
and throat (ent) examination is not a routinely per-
formed procedure, ent involvement of pemphigus 
generally remains unrecognized. the ent mucosa are 
well-known involvement areas for PV; its frequency, 
however, has been investigated only in a limited 
number of studies (1-6). Moreover, the relationship 
between ent involvement and pemphigus scoring 
systems, i.e. Pemphigus Disease Area index (PDAi) 
and Autoimmune Bullous skin Disorder intensity 
score (ABsis), has not yet been investigated.
this study was designed to evaluate the real ex-
tent of PV involvement, the effect of routine ent 
examination on pemphigus scoring systems, and to 
find out the optimal scores which indicate the need 
for ent examination.
PATIENTS AND METHODS 
Patients with PV attending the Dermatology Out-
patient Clinic during the period between December 
2015 and June 2016 were included in the current 
cross-sectional study, after approval of the research 
ethics Committee Office (70904504/66). those pa-
tients with clinical conditions described below were 
selected to participate in the study:
i)  Patients with a new diagnosis of PV who were 
not treated previously.
ii)  Patients with clinical exacerbation.
iii) Patients in clinical remission (7).
A full detailed written consent for participation 
and endoscopic examinations was retrieved before 
inclusion in the study. Diagnosis of PV was based on a 
combination of clinical and histopathological exami-
nation, as well as direct immunofluorescence findings 
for skin or oral lesions. the subtypes of PV were iden-
tified as mucosal PV (MPV) and mucocutaneous PV 
(MCPV) according to clinical and immunological fea-
tures. the patients were asked whether they had oral, 
ear, nose, and throat symptoms, and all of them were 
evaluated for ent manifestations by direct and endo-
scopic examination. ent examinations were carried 
out by one fixed otolaryngologist (from among the 
researchers).
Patients with a new diagnosis or exacerbation 
were accepted as active disease participants; patients 
on remission were accepted as control subjects. the 
clinical activity of the PV was evaluated by PDAi and 
ABsis (8).  the activity scores of the ent involvement 
were calculated by a method adapted from the muco-
sal scoring method in PDAi (table 1). to evaluate the 
relationship between ent scores and disease sever-
ity, cut-off values for PDAi and ABsis were accepted 
as those defined in the recent study of Boulard et al. 
(9). the cut-off values distinguishing moderate, sig-
nificant, and extensive pemphigus suggested were 
15 and 45 for PDAi and 17 and 53 for ABsis. since ex-
tensive disease was so limited, we only used cut-off 
values of 15 for PDAi and 17 for ABsis.
the results were expressed as mean± sD or medi-
an (min-max) for quantitative data and as frequencies 
(number and percent) for categorical findings. statis-
tical analysis of clinical data between the two groups 
consisted of unpaired t-tests for parametric data and 
Mann Whitney U-test analysis for nonparametric 
data. these were used to determine the strength of 
correlation between the ent, PDAi, and ABsis scores. 
in addition, proportions were compared according to 
either the Chi-square or fisher exact test. results were 
considered significant at 5% critical values (P<0.05). 
All data were analysed using the statistical program 
sPss 22 (iBM sPss statistics for Windows, Version 
22.0. Armonk, nY: iBM Corp.).
RESULTS
in total, 50 patients (20 men and 30 women) were 
enrolled in this study. the mean age was 48.0±11.21 
(mean ± standard Deviation; range: 26-76) years 
and the mean duration of disease was 32.66±36.66 
months, with a range of 1 to 144 months. thirty-eight 
patients had active disease and 12 patients were in 
remission. Of the 38 active patients, 20 were newly 
diagnosed, while 18 were experiencing disease ex-
acerbation. Of the 50 patients, 20 (12 active disease, 
8 patients in remission) had MPV and 30 (26 ac-
tive disease, 4 patients in remission) had MCPV. the 
mean PDAi, ABsis, and ent scores were 18.82±23.71, 
20.13±20.87, and 9.97±11.10 in patients with MCPV 
and 7.56±15.18, 7.30±14.80, 11.44±17.94 in patients 
with MPV respectively. 
symptoms of ent involvement were most com-
monly described as oral pain (or discomfort) (68%), 
dysphonia (58%), or dysphagia (54%) (table 2). Al-
though it was not the case for all patients, there was a 
significant correlation between clinical symptomatol-
ogy and endoscopic findings (figure 1). endoscopic 
findings were significantly associated and highly 
correlated with oral pain, dysphagia, and nasal ob-
struction (P<0.05). Oral symptomatology and find-
ings were significantly more frequent in patients with 
MCPV than with MPV (P<0.05).  
ent scores were found to be highly correlated 
with PDAi total activity scores (r=0.716, P<0.05), PDAi 
mucosal scores (r=0.918, P<0.05) and ABsis mucosal 
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scores (r=0.869, P<0.05), but only moderately corre-
lated with ABsis total scores (r=0.660, P<0.05). the se-
verity of the mucosal involvement obtained by PDAi 
and / or ABsis was not an exact indicator of disease 
severity. the mean ent scores were 3.86±5.62 and 
4.68±8.28 in patients with PDAi <15 and ABsis <17, 
respectively. the mean ent score was 22.46±16.73 
and 20.14±16.41 in patients with PDAi ≥15 and ABsis 
≥17, respectively (P<0.05) (figure 2, figure 3).
there was no correlation between the duration 
of disease and the severity of involvement in terms 
of PDAi, ABsis, and ent scores (P>0.05) regardless of 
the subtype of pemphigus (MPV or MCPV) or the type 
of patient (newly diagnosed or in exacerbation).
DISCUSSION
Our study found that the severity of ent involve-
ment in PV was significantly associated with ent en-
doscopic findings and symptoms, especially for PDAi 
≥15 and / or ABsis ≥17. this is the first report to iden-
tify the correlation between internationally accepted 
pemphigus scoring tools (PDAi and ABsis) and sever-
ity of ent involvement. involvement of ent mucosa 
in PV significantly increases patient morbidity. several 
studies in the literature have attempted to define the 
frequency of ent involvement (1-6), the main out-
come being that the frequency of ent involvement 
was higher than expected in these studies. similarly, 
all the studies agree that endoscopic ent findings 
show a greater frequency of clinically active PV le-
sions than the symptoms reported for each mucosa 
individually (1-6). 
All reports, including our study, identified that 
oral, pharyngeal, and laryngeal symptoms were the 
most common symptoms respectively (table 3) (1-6). 





5: >3 lesions or 2 lesions>2 cm
10: entire area









Table 2. frequency of ear, nose, and throat symp-
toms in patients with pemphigus vulgaris
Symptoms Frequency, n (%)
Oral 








Nose obstruction 19 (38)
Bloody mucus 15 (30)
Nasal stuffiness 14 (28)
Hyposmia / dysosmia 2 (4)
Ear
Otalgia  0
Ear blockage 5 (10)
Hypoacusi 0
Figure 1. Clinical symptomatology and endoscopic findings 
of the patients.
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Conversely, the least frequent symptoms were relat-
ed to the ear. there are only two prospective studies 
in which the relationship between the severity of PV 
and ent mucosa involvement had been investigated 
in the literature (1,4). ent involvement was not asso-
ciated with the severity and clinical improvement of 
the disease in the study of Kavala et al. in their evalu-
ation of 38 patients with active PV (4). in this study, 
a severity scoring system was used to evaluate eight 
body surface areas for disease severity. the severity 
was scored as mild, moderate, or severe, according to 
the number of involved areas (mild ≤3, moderate 4-6, 
and severe ≥7). no relation between disease severity 
and ent involvement was found. However, since the 
scoring system used in this study was not a validated 
tool for the determination of disease severity, such as 
PDAi, the value of the results of this study is some-
what debatable. fawzy et al. used a different scoring 
system to calculate disease severity: the pemphigus 
area and activity score (PAAs) (1,10). they also added 
a grading of free, mild, moderate, and severe in terms 
of the number of involved body sites. According to 
their results, there was no correlation between muco-
sal involvement and disease severity. However, they 
also concluded that the disease duration is the main 
determiner for the severity of mucosal involvement 
in patients with PV, because they showed a positive 
correlation between the duration of the disease and 
the severity of the involvement with no relevance 
to the type of pemphigus (MPV or MCPV) or the 
type of patient (newly diagnosed or in exacerba-
tion) (1). in contrast, our study did not demonstrate a 
Table 3. Oral mucosa and ear, nose, and throat manifestations in published series
Published series
Symptoms / Endoscopic findings (%)
Oral mucosa Pharynx Larynx Nasal mucosa Ear
Hale and Bystryn (6)
(n=50/11*)
-/- -/- 39.6/57.0 22.6/75.0 -/-
espana et al. (5)
(n=16)
93.7/93.7 75/62.5 44.0/75.0 38.0/75.0 18.7/18.7
Kavala et al. (4)
(n=38)
100.0/97.4 81.6/65.8 38.7/55.3 81.6/76.3 2.6/10.5
fernandez et al. (3)
(n=40)
92.5/92.5 75/85 42.5/85.0 47.5/70.0 7.5/7.5
robati et al. (2)
(n=41)
75.6/90.2 70.7/61 39.0/58.5 -/36.6 26.8/26.8
fawzy et al. (1)
(n=34)
67.6/100.0 56/76.5 14.7/76.5 29.4/32.4 26.5/26.5
Current study
(n=50)
68.0/64.0 56/48 58.0/46.0 50.0/48.0 10.0/10.0
*This series includes 53 patients but only 11 were studied by laryngeal and nasal endoscopy.
Figure 2. Correlation between ear, nose, and throat (ent) 
score and disease severity detected by Pemphigus Disease 
Area index (PDAi).
Figure 3. Correlation between ear, nose, and throat (ent) 
score and disease severity detected by Autoimmune Bul-
lous skin Disorder intensity score (ABsis).
Bilgic-temel et al. Acta Dermatovenerol Croat
PV severity scores indicating ent damage  2018;26(4):283-288
286
287
statistically significant correlation between the du-
ration of the disease and the severity of the involve-
ment. this discrepancy could be explained by the in-
dividual differences in clinical courses of the disease 
between the patients in the study groups. it is prob-
able that the previous two studies mostly consisted 
of patients with progressive disease; conversely, ours 
consisted of patients who had mostly stable and clini-
cally persistent disease. in the study by espana et al. 
10 patients with the mucosal form of PV (MPV) and 
6 with the mucocutaneous form of PV (MCPV) were 
evaluated by endoscopic examination and reported 
more frequent laryngeal involvement in the mucosal 
form than in the mucocutaneous form of patients 
with PV (5). However, in our study, oral pain and oral 
endoscopic findings were reported as being more 
frequent in patients with MCPV than with MPV. Also, 
all the other ent symptoms were reported as be-
ing more frequent in patients with MCPV, although 
the result was not statistically significant. this could 
be related to the result that the mean PDAi and AB-
sis scores of patients with MCPV were significantly 
higher than in patients with MPV among our sub-
jects. However, there was no significant difference 
between the mean ent scores of patients with MCPV 
and MPV. fernandez et al. investigated the relation 
between anatomical locations and trauma for the 
development of mucosal lesions in patients with PV 
(3). they suggested keeping in mind that trauma pro-
duced by the very dynamic of the anatomical struc-
tures involved in the functions of the upper aero di-
gestive tract may exert an influence on the severity of 
PV lesions. the results of current and previous studies 
have indicated that the probable cause of the devel-
opment of more frequent oropharyngeal lesions than 
lesions in other anatomical sites such as ear and nose 
is the effect of physiological trauma in oropharyngeal 
region. therefore, patients should be informed about 
the role of traumatic physiological mechanisms to 
avoid the appearance of new mucosal lesions (3). ro-
bati et al. evaluated new patients with PV before and 
after treatment by endoscopic examination (2). this 
study demonstrated that endoscopic ent examina-
tion is useful not only in finding out the extent of the 
disease and its severity, but also for evaluation of the 
effectiveness of the treatment.
As a result of these studies, full ent examination 
leads to a more accurate diagnosis of the severity and 
extent of the disease. However, our study has addi-
tionally uncovered the specific scores which indicate 
the ent involvement, obtained via the recently vali-
dated and accepted scoring systems. 
Limitations
the primary limitation of our study would be the 
lack of endoscopic biopsies, although we demon-
strated acantholytic cells by cytology which was per-
formed in the course of endoscopic examination.  
CONCLUSIONS
identification of the exact severity of ent involve-
ment in patients with PV plays a role in the prediction 
of prognosis and may serve as a guide for its man-
agement. However, as endoscopic ent examination 
cannot become a routinely performed procedure be-
cause of time and economic issues, performing such 
an examination should nonetheless be considered in 
patients, especially for PDAi ≥15 and / or ABsis ≥17, 
regardless of ent symptoms.
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